Logo image of ABVX.PA

ABIVAX SA (ABVX.PA) Stock Fundamental Analysis

EPA:ABVX - FR0012333284 - Common Stock

76.5 EUR
+3.7 (+5.08%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

2

ABVX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. ABVX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ABVX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABVX had negative earnings in the past year.
In the past year ABVX has reported a negative cash flow from operations.
In the past 5 years ABVX always reported negative net income.
In the past 5 years ABVX always reported negative operating cash flow.
ABVX.PA Yearly Net Income VS EBIT VS OCF VS FCFABVX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -85.88%, ABVX is doing worse than 74.32% of the companies in the same industry.
Looking at the Return On Equity, with a value of -434.26%, ABVX is doing worse than 68.92% of the companies in the same industry.
Industry RankSector Rank
ROA -85.88%
ROE -434.26%
ROIC N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX.PA Yearly ROA, ROE, ROICABVX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

ABVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX.PA Yearly Profit, Operating, Gross MarginsABVX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ABVX has more shares outstanding
The number of shares outstanding for ABVX has been increased compared to 5 years ago.
The debt/assets ratio for ABVX is higher compared to a year ago.
ABVX.PA Yearly Shares OutstandingABVX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX.PA Yearly Total Debt VS Total AssetsABVX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 14.72 indicates that ABVX is not in any danger for bankruptcy at the moment.
ABVX's Altman-Z score of 14.72 is amongst the best of the industry. ABVX outperforms 91.89% of its industry peers.
A Debt/Equity ratio of 1.29 is on the high side and indicates that ABVX has dependencies on debt financing.
The Debt to Equity ratio of ABVX (1.29) is worse than 62.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z 14.72
ROIC/WACCN/A
WACCN/A
ABVX.PA Yearly LT Debt VS Equity VS FCFABVX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.82 indicates that ABVX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.82, ABVX perfoms like the industry average, outperforming 43.24% of the companies in the same industry.
A Quick Ratio of 1.82 indicates that ABVX should not have too much problems paying its short term obligations.
ABVX has a Quick ratio (1.82) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
ABVX.PA Yearly Current Assets VS Current LiabilitesABVX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

ABVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.74%, which is quite good.
EPS 1Y (TTM)16.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ABVX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.85% on average per year.
Based on estimates for the next years, ABVX will show a very strong growth in Revenue. The Revenue will grow by 153.98% on average per year.
EPS Next Y3.43%
EPS Next 2Y26.23%
EPS Next 3Y-1.36%
EPS Next 5Y32.85%
Revenue Next Year124.58%
Revenue Next 2Y19.15%
Revenue Next 3Y226.97%
Revenue Next 5Y153.98%

3.3 Evolution

ABVX.PA Yearly Revenue VS EstimatesABVX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
ABVX.PA Yearly EPS VS EstimatesABVX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX.PA Price Earnings VS Forward Price EarningsABVX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX.PA Per share dataABVX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.23%
EPS Next 3Y-1.36%

More info and screens

0

5. Dividend

5.1 Amount

ABVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIVAX SA

EPA:ABVX (9/5/2025, 7:00:00 PM)

76.5

+3.7 (+5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-02 2025-06-02
Earnings (Next)09-08 2025-09-08
Inst Owners42.26%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.78B
Analysts87.69
Price Target88.23 (15.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)145.33%
PT rev (3m)129.17%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)7.7%
EPS NY rev (3m)7.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)205.77%
Revenue NY rev (3m)-67.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 142.45
P/tB 371.58
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)-2.57
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0
BVpS0.54
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.88%
ROE -434.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z 14.72
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.47%
EPS Next Y3.43%
EPS Next 2Y26.23%
EPS Next 3Y-1.36%
EPS Next 5Y32.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year124.58%
Revenue Next 2Y19.15%
Revenue Next 3Y226.97%
Revenue Next 5Y153.98%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.9%
EBIT Next 3Y29.55%
EBIT Next 5Y40.7%
FCF growth 1Y-58.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.62%
OCF growth 3YN/A
OCF growth 5YN/A